

Angelo Iacobellis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7197364/publications.pdf>

Version: 2024-02-01

29
papers

1,191
citations

516681

16
h-index

501174

28
g-index

29
all docs

29
docs citations

29
times ranked

1537
citing authors

#	ARTICLE	IF	CITATIONS
1	Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study. <i>Journal of Hepatology</i> , 2007, 46, 206-212.	3.7	188
2	Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 624-632.	1.0	130
3	Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (Lâ€PLUS 2). <i>Hepatology</i> , 2019, 70, 1336-1348.	7.3	111
4	Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 397-404.	3.7	104
5	Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 927-933.	1.0	93
6	Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. <i>European Journal of Internal Medicine</i> , 2017, 38, 79-82.	2.2	92
7	IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. <i>Cytokine</i> , 2004, 25, 103-109.	3.2	90
8	Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2006, 12, 7821.	3.3	48
9	Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 769-774.	3.7	46
10	HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 620-628.	3.7	43
11	External Validation of Biochemical Indices for Noninvasive Evaluation of Liver Fibrosis in HCV Chronic Hepatitis. <i>American Journal of Gastroenterology</i> , 2005, 100, 868-873.	0.4	34
12	Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 249-253.	4.4	34
13	Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 146-153.	3.7	28
14	Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. <i>World Journal of Gastroenterology</i> , 2008, 14, 6467.	3.3	26
15	Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13508.	3.4	20
16	Treatment of patients with HCV infection with or without liver biopsy. <i>Journal of Viral Hepatitis</i> , 2004, 11, 536-542.	2.0	19
17	Long-term outcome of hepatitis B virus-related chronic hepatitis under protracted nucleos(t)ide analogues. <i>Journal of Viral Hepatitis</i> , 2013, 20, 502-509.	2.0	16
18	Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1929-1938.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 331-337.	3.7	10
20	Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: A pilot study. <i>Digestive and Liver Disease</i> , 2007, 39, 857-863.	0.9	7
21	Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1371-1382.	2.3	7
22	Early discontinuation of ribavirin in HCV α 2 and HCV α 3 patients responding to Peg α 2a and ribavirin. <i>Journal of Viral Hepatitis</i> , 2009, 16, 28-35.	2.0	6
23	The intelligent, painless, "germ-free" colonoscopy: A Columbus TM egg for increasing population adherence to colorectal cancer screening?. <i>Digestive and Liver Disease</i> , 2010, 42, 839-843.	0.9	6
24	Unawareness of HBV infection among inpatients in a Southern Italian hospital. <i>Journal of Viral Hepatitis</i> , 2011, 18, e206-11.	2.0	6
25	Hepatitis C Virus Clearance in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 85-91.	2.6	6
26	Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. <i>World Journal of Hepatology</i> , 2016, 8, 949.	2.0	5
27	Crystallization and preliminary crystallographic data for the augmenter of liver regeneration. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 1997, 53, 331-334.	2.5	4
28	Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia. <i>Digestive and Liver Disease</i> , 2014, 46, 621-624.	0.9	1
29	Unusual sonographic appearance of a haemorrhagic biliary cyst. <i>European Journal of Radiology Extra</i> , 2005, 54, 103-105.	0.1	0